🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a ...
Status
Completed
Location
Beijing Anzhen Hospital，Capital Medical University
Start Date
2022-02-28
Trial ID
NCT05532800
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody....
Status
Completed
Location
Fuwai Hospital Chinese Academy of Medical Sciences
Start Date
2019-05-23
Trial ID
NCT04469673
Treatments Being Tested
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a...
Status
Completed
Location
Fuwai Hospital Chinese Academy of Medical Sciences
Start Date
2017-12-11
Trial ID
NCT04197817
This study was a single-center, randomized, open-label, single-dose, parall...
Status
Completed
Location
Shenzhen Third People's Hospital
Start Date
2023-05-30
Trial ID
NCT05859529
Treatments Being Tested
This open-label phase I clinical study with clinical development phase will...
Status
Terminated
Location
Henan Tumor Hospital
Start Date
2022-02-10
Trial ID
NCT05128539
Treatments Being Tested
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a ...
Status
Completed
Location
The First Affiliated Hospital of Bengbu Medical College
Start Date
2020-12-23
Trial ID
NCT04781114
JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II ...
Status
Completed
Location
Beijing Anzhen Hospital Capital Medical University
Start Date
2020-08-17
Trial ID
NCT04515927
Treatments Being Tested
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a ...
Status
Recruiting
Location
Peking University Third Hospital
Start Date
2023-02-03
Trial ID
NCT05621070
JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a ...
Status
Completed
Location
Beijing Anzhen Hospital Capital Medical University City:Beijing
Start Date
2021-12-31
Trial ID
NCT05325203
Treatments Being Tested